China News Agency, Moscow, December 21 (Reporter Wang Xiujun) The Russian "Satellite-V" vaccine developer Gamallea National Research Center for Epidemiology and Microbiology (Gamallea Center) Director Günzburg said on the 21st that Gamaliel Subcenter and AstraZeneca Pharmaceuticals of the United Kingdom are about to combine their vaccines for clinical trials.
The "Satellite-V" vaccine developed by the Gamaliel Center is a human adenovirus vector vaccine, which consists of two adenovirus vectors.
The AZD1222 vaccine developed by AstraZeneca and Oxford University, like the "Satellite-V" vaccine, is also an adenovirus vector vaccine.
Previously, the Gamaliea Center proposed to AstraZeneca to combine its own vaccine with the "Satellite-V" vaccine during the trial, that is, to inject the AZD1222 vaccine and the "Satellite-V" vaccine on a volunteer. Thereby improving the effectiveness of the vaccine.
On the 21st, the Gamallea Center and AstraZeneca, the Russian Direct Investment Fund (cooperative manufacturer of vaccines) and the Russian pharmaceutical company "R-Pharm" signed a memorandum of cooperation in fighting the new crown epidemic through a video connection.
Russian President Putin attended the connection event.
Günzburg said on the same day that both parties will start clinical trials.
This trial will not consume too much money and time, because the vaccines used in the Gamaleia Center are similar to those used by AstraZeneca's vaccines, and the two sides are compatible.
AstraZeneca’s global CEO Subko said on the same day that the combination of the two vaccines will enhance the immune effect of the vaccine, which is beneficial to both parties.
Putin congratulated the two parties on signing the memorandum of cooperation and said that this cooperation model should become a model for other vaccine manufacturers.
Such cooperation should not be based on policy, but on the safety and effectiveness of vaccines.
In addition, Putin emphasized that according to existing information, the "Satellite-V" vaccine also has an immune effect against the mutant new coronavirus discovered in the UK.
(Finish)